Contemporary Issues in Lung CancerJones & Bartlett Publishers, 2009 M02 12 - 364 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective Second Edition is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. |
From inside the book
Results 1-5 of 74
Page 5
... Table 1–4 Stage. Epidemiology. of. Lung. Cancer. In the United States, lung cancer is the second most common cancer diagnosed in men and women today (Jemal, et al., 2008). The American Cancer Society estimates there will be 215,020 new ...
... Table 1–4 Stage. Epidemiology. of. Lung. Cancer. In the United States, lung cancer is the second most common cancer diagnosed in men and women today (Jemal, et al., 2008). The American Cancer Society estimates there will be 215,020 new ...
Page 6
... Table 1–2 Source: SEER, data 2001–2005. Adenocarcinoma represents about 40% of lung cancer cases in the 6 Chapter 1: Separating Out the Differences Between Lung Cancers. Age Percentage at Diagnosis Percentage at Death 20 years 0 % 0 % 20 ...
... Table 1–2 Source: SEER, data 2001–2005. Adenocarcinoma represents about 40% of lung cancer cases in the 6 Chapter 1: Separating Out the Differences Between Lung Cancers. Age Percentage at Diagnosis Percentage at Death 20 years 0 % 0 % 20 ...
Page 7
Marilyn Haas. Table 1–4 Stage Distribution at Lung Cancer Diagnosis Time at Diagnosis 5-Year Survival Rates Local 16% 49.5% Regional 25% 20.6% Distant 51% 2.8% Unknown 8% 8.3% (unstaged) Table 1–5 AJCC Staging of Lung Cancer Primary ...
Marilyn Haas. Table 1–4 Stage Distribution at Lung Cancer Diagnosis Time at Diagnosis 5-Year Survival Rates Local 16% 49.5% Regional 25% 20.6% Distant 51% 2.8% Unknown 8% 8.3% (unstaged) Table 1–5 AJCC Staging of Lung Cancer Primary ...
Page 8
... Table 1–7) (Goldstraw, et al., 2007). This will change the staging as well (Table 1–8) (Goldstraw, et al., 2007). Risk. Factors. Lung cancer is one of the few cancers that have identified, specific, known carcinogens. Epidemiological ...
... Table 1–7) (Goldstraw, et al., 2007). This will change the staging as well (Table 1–8) (Goldstraw, et al., 2007). Risk. Factors. Lung cancer is one of the few cancers that have identified, specific, known carcinogens. Epidemiological ...
Page 9
Marilyn Haas. Table. 1–5. AJCC Staging of Lung Cancer Primary Tumor (T) TX Primary tumor cannot be assessed, or tumor is proven by the presence of malignant cells in ... Table 1–6 Stage Grouping Stage grouping of the TNM subsets Risk Factors ...
Marilyn Haas. Table. 1–5. AJCC Staging of Lung Cancer Primary Tumor (T) TX Primary tumor cannot be assessed, or tumor is proven by the presence of malignant cells in ... Table 1–6 Stage Grouping Stage grouping of the TNM subsets Risk Factors ...
Contents
Oncology Treatment Modalities | 45 |
Special Issues Facing Individuals with Lung Cancer | 117 |
Psychosocial Issues of Individuals with Lung Cancer | 231 |
Assistance and Resources for Individuals Facing Lung Cancer | 255 |
Media and Future Research Directions | 301 |
Index | 353 |
Other editions - View all
Common terms and phrases
adjuvant agents aprepitant associated bevacizumab breathing breathlessness Bruera carboplatin carcinoma cell lung cancer chemotherapy chronic cisplatin Clinical Oncology clinical trials combination diagnosis disease docetaxel dose drug dyspnea EGFR erlotinib etoposide evaluation evidence-based factors fatigue gefitinib gemcitabine gene improve increased individuals indoor radon Internet intervention irinotecan Journal of Clinical lung cancer patients Medicine ment metastatic months NCCN nicotine non-small cell lung NSCLC Nursing Forum Oncology Nursing Oncology Nursing Forum paclitaxel palliative palliative care patient navigation patients and families patients with lung pemetrexed phase postoperative potential pulmonary quit smoking radiation therapy radiotherapy radon randomized receptors regimen reported resection respiratory response rate risk role SCLC score screening Sekido side effects small cell lung smoking cessation stage strategies support group surgical survival rate Symptom Management Table tients tion tobacco topotecan toxicity treat treatment tumor versus vinorelbine weight loss